Vergoeding 2018-2022 voor ATC-subgroep C10AX : Overige antilipaemica
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| C10AX09 Ezetimib (Ezetrol ®) | 28.255.700 | 7.315.400 | 6.299.100 | 4.933.200 | 5.306.900 |
| C10AX12 Lomitapide (Lojuxta ®) | 1.499.400 | 1.530.800 | 1.563.700 | 2.142.400 | 1.920.500 |
| C10AX13 Evolocumab (Repatha ®) | 33.398.200 | 39.992.200 | 48.228.100 | 55.537.900 | 66.453.700 |
| C10AX14 Alirocumab (Praluent ®) | 20.154.800 | 30.221.700 | 41.013.500 | 47.665.500 | 58.353.900 |
| C10AX16 Inclisiran (Leqvio ®) | . | . | . | . | 2.806.600 |
| Totaal | 83.308.100 | 79.060.100 | 97.104.400 | 110.279.000 | 134.841.600 |